Stem cell advocates anticipate FDA roundtables as peptide therapies gain regulatory foothold

At PepMed 2026, a conference focused on peptide medicines, stem cell entrepreneur Chuck Meeker said he expects the FDA to hold a series of roundtables on regenerative therapies before year‑end.

He cited the recent regulatory acceptance of compounded peptides, which have been embraced by the American Academy of Peptide Medicine (MAHA), as a model for how stem‑cell products might eventually gain formal oversight.

While Meeker is optimistic, the FDA declined to comment on any planned meetings, and many stem‑cell treatments currently marketed remain unapproved and are viewed as experimental.

Advocates see the potential roundtables as a step toward clearer guidance, but the industry still faces uncertainty about how the agency will address safety and efficacy concerns.